Pharmacokinetic Estimation Models-based Approach to Predict Clinical Implications for CYP Induction by Calcitriol in Human Cryopreserved Hepatocytes and HepaRG Cells
Open Access
- 29 January 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (2) , 181
Abstract
Calcitriol, a vitamin D3 metabolite, is approved for various indications because it is the bioactive form of vitamin D in the body. The purpose of this study was to predict the clinical significance of cytochrome P450 (CYP) induction by calcitriol using in vitro human cryopreserved hepatocytes, HepaRG experimental systems, and various pharmacokinetic estimation models. CYP2B6, 3A4, 2C8, and 2C9 mRNA levels increased in a concentration-dependent manner in the presence of calcitriol in human cryopreserved hepatocytes and HepaRG cells. Using the half maximal effective concentration (EC50) and maximum induction effect (Emax) obtained from the in vitro study, a basic kinetic model was applied, suggesting clinical relevance. In addition, a static mechanistic model showed the improbability of a clinically significant effect; however, the calculated area under the plasma concentration–time curve ratio (AUCR) was marginal for CYP3A4 in HepaRG cells. To clarify the effect of CYP3A4 in vivo, physiologically based pharmacokinetic (PBPK) modeling was applied as a dynamic mechanistic model, revealing a low clinically significant effect of CYP3A4 induction by calcitriol. Therefore, we conclude that CYP induction by calcitriol treatment would not be clinically significant under typical clinical conditions.Keywords
Funding Information
- Gachon University Research Fund of 2020 (GCU-2020-02450001)
- Korea Research Institute of Bioscience and Biotechnology (KRIBB) Research Initiative Programs (KGM5212022)
This publication has 72 references indexed in Scilit:
- Cytochrome P450 3A4 mRNA Is a More Reliable Marker than CYP3A4 Activity for Detecting Pregnane X Receptor-Activated Induction of Drug-Metabolizing EnzymesDrug Metabolism and Disposition, 2010
- Cytochrome P450-mediated metabolism in the human gut wallJournal of Pharmacy and Pharmacology, 2009
- Cytochrome P450-mediated metabolism in the human gut wallJournal of Pharmacy and Pharmacology, 2009
- Cytochrome P450 and Chemical ToxicologyChemical Research in Toxicology, 2007
- Misuse of the Well-Stirred Model of Hepatic Drug ClearanceDrug Metabolism and Disposition, 2007
- A Phase I Pharmacokinetic and Pharmacodynamic Study of Intravenous Calcitriol in Combination with Oral Gefitinib in Patients with Advanced Solid TumorsClinical Cancer Research, 2007
- High dose calcitriol may reduce thrombosis in cancer patientsBritish Journal of Haematology, 2006
- EXPRESSION AND INDUCTION POTENTIAL OF CYTOCHROMES P450 IN HUMAN CRYOPRESERVED HEPATOCYTESDrug Metabolism and Disposition, 2005
- Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitorsThe American Journal of Cardiology, 2004
- 1,25-Dihydroxyvitamin D3 inhibitory effect on the growth of two human breast cancer cell lines (MCF-7, BT-20)Journal of Steroid Biochemistry, 1986